<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822795</url>
  </required_header>
  <id_info>
    <org_study_id>PD12133</org_study_id>
    <nct_id>NCT01822795</nct_id>
  </id_info>
  <brief_title>Lung Volume Reduction Coil Treatment in Emphysema.</brief_title>
  <acronym>STICREVOLENS</acronym>
  <official_title>Cost-effectiveness of Lung Volume Reduction Coil Treatment in Emphysema.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PneumRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  BACKGROUND: Medical therapeutic options for the treatment of emphysema remain limited.
           Lung volume reduction surgery is infrequently used because of its high morbi-mortality.
           Endobronchial lung volume reduction coil (LVRC(®), PneumRx, Mountain View, CA) treatment
           has been recently developed and has been shown to be feasible and associated with an
           acceptable safety profile, while resulting in improvements in dyspnea, exercise capacity
           and lung function. The objective of this study is to analyze the cost effectiveness of
           LVRC treatment in severe emphysema.

        -  METHODS:This prospective, multicenter study, randomized with a 1:1 ratio (LVRC vs
           conventional treatment) will include 100 patients who will be followed up for 1year. The
           primary outcome measure is the 6-month improvement of the 6-minute walk test: the
           percentage of patients showing an improvement of at least 54m will be compared between
           groups. A cost-effectiveness study will estimate the cost of LVRC treatment, the global
           cost of this therapeutic option and will compare the cost between patients treated by
           LVRC and by medical treatment alone.

        -  EXPECTED RESULTS:This study should allow validating the clinical efficacy of LVRC in
           severe emphysema. The cost-effectiveness study will assess the medical-economic impact
           of the LVRC therapeutic option.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-month improvement of the 6-minute walk test</measure>
    <time_frame>6 months</time_frame>
    <description>6-month improvement of the 6-minute walk test : the percentage of patients showing an improvement of at least 54m will be compared between groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Cost utility (incremental cost effectiveness ratio) of each therapeutic option according to the EuroQol-5 dimensions (EQ-5D) utility scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison of dyspnea assessed by the mMRC scale, BDI/TDI scale and the Borg scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function assessment</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Pulmonary function tests including FEV1, FVC, RV, TLC, RV/TLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison of the St georges questionnaire score and the EuroQoL 5D (European Quality of Life 5 dimensions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity-mortality</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison of mortality and severe adverse events using a composite score (death, haemoptysis &gt; 150 cc, pneumonia requiring hospitalization, pneumothorax requiring chest tube drainage &gt; 7 days, mechanical ventilation &gt; 24 hours, lung transplantation).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exercise testing</measure>
    <time_frame>6 and 12 months months</time_frame>
    <description>Comparison of the 6-min walking test between groups (using the &gt; 25 meters change from baseline as cut-off for clinically significant change).</description>
  </other_outcome>
  <other_outcome>
    <measure>Exercise testing</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of the 6-min walking distance at 12 months using 54 meters as cut-off for clinically significant change.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Lung volume reduction coïl treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lung volume reduction coïl treatment,added to usual medical treatment and follow up after the intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular Medical Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No intervention, just a follow up under usual medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lung volume reduction coïl treatment</intervention_name>
    <arm_group_label>Lung volume reduction coïl treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Regular medical treatment</intervention_name>
    <arm_group_label>Lung volume reduction coïl treatment</arm_group_label>
    <arm_group_label>Regular Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bilateral emphysema on Chest CT Scanner

          -  Post bronchodilator FEV1 &lt; 50 %

          -  Total Lung Capacity &gt; 100 %

          -  Residual Volume &gt; 220 %

          -  Dyspnea score between 2 and 4 based on the mMRC scale

          -  Stopped cigarette smoking for more than 8 weeks

          -  Pulmonary rehabilitation within the previous twelve months

          -  Consent form signed

          -  Covered by Medical Insurance

        Exclusion Criteria:

          -  Post bronchodilator FEV1 &lt; 15%

          -  Post-bronchodilator change in FEV1 &gt; 20%

          -  Severe recurrent respiratory infections requiring more than 2 hospitalization stays
             within the past twelve months

          -  COPD exacerbation requiring hospital stay within 3 months

          -  Pulmonary Hypertension (Pulmonary systolic pressure &gt;50 mmHg on cardiac echo)

          -  Patient unable to perform a 6-min walking test in room air

          -  Giant bulla of more than 1/3 of the lung field on Chest CT

          -  Strictly homogeneous emphysema on Chest CT

          -  Clinically significant bronchiectasis

          -  Past history of lobectomy, lung volume reduction surgery, lung transplantation

          -  Any extrapulmonary diseases compromising survival or evaluation within the protocol
             (severe cardiac disease, severe renal insufficiency, cancer…)

          -  Lung carcinoma or pulmonary nodule on CT scan requiring Chest CT scan follow-up

          -  Contra-indication to general anesthesia

          -  Oral anticoagulant treatment (antivitamin K)

          -  Allergy to nitinol

          -  Inclusion in an other study assessing respiratory treatments

          -  Patient protected by the law
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaëtan DESLEE, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Reims</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>AMIENS Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>GRENOBLE Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>MONTPELLIER Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital Bichat</name>
      <address>
        <city>PARIS Cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>ROUEN Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-priest-en-jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>STRASBOURG Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.euroemphysema.com</url>
  </link>
  <reference>
    <citation>Deslee G, Barbe C, Bourdin A, Durand-Zaleski I, Dutau H, Jolly D, Jounieaux V, Kessler R, Mal H, Pison C, Thiberville L, Vergnon JM, Marquette CH. [Cost-effectiveness of lung volume reduction coil treatment in emphysema. STIC REVOLENS]. Rev Mal Respir. 2012 Nov;29(9):1157-64. doi: 10.1016/j.rmr.2012.09.010. Epub 2012 Oct 12. French.</citation>
    <PMID>23200592</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2013</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>Endoscopic lung volume reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

